ストックスクリーナーアプリを入手
6.295
5.48%
-0.365
アフターアワーズ：
6.39
0.095
+1.51%
前日終値:
$6.66
開ける：
$6.63
24時間の取引高:
109.18K
Relative Volume:
1.00
時価総額：
$23.18M
収益：
-
当期純損益:
$-31.11M
株価収益率:
-4.1144
EPS:
-1.53
ネットキャッシュフロー:
$-28.18M
1週間 パフォーマンス:
-9.42%
1か月 パフォーマンス:
-8.77%
6か月 パフォーマンス:
-47.69%
1年 パフォーマンス:
-75.17%
1日の値動き範囲:
$6.25
$6.69
1週間の範囲:
$6.25
$7.0497
52週間の値動き範囲:
$5.3495
$28.34
Tempest Therapeutics Inc Stock (TPST) Company Profile
名前
Tempest Therapeutics Inc
セクター
電話
415-798-8589
住所
2000 SIERRA POINT PARKWAY, BRISBANE
TPST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
6.295 | 25.59M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-02-08 | 開始されました | Jefferies | Buy |
Tempest Therapeutics Inc (TPST) 最新ニュース
Tempest Therapeutics Inc. Stock Analysis and ForecastMassive wealth growth - Jammu Links News
Is Tempest Therapeutics Inc. a good long term investmentExceptional financial outcomes - Jammu Links News
What analysts say about Tempest Therapeutics Inc. stockPowerful growth strategies - Jammu Links News
Is Tempest Therapeutics Inc. stock a growth or value playSmart High Yield Swing Trades - Newser
What drives Tempest Therapeutics Inc. stock priceHigh-yield capital appreciation - Jammu Links News
Why Tempest Therapeutics Inc. stock attracts strong analyst attentionPrecision Entry Strategy - Newser
What makes Tempest Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
How Tempest Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
Head-To-Head Contrast: Tempest Therapeutics (NASDAQ:TPST) vs. Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Tempest Therapeutics (NASDAQ:TPST) Trading Up 0.2% – Here’s Why - Defense World
Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment - TipRanks
Tempest Receives Clearance to Proceed with Pivotal Trial of - GlobeNewswire
Millennium Management LLC Acquires Shares of 189,506 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics Secures $4.1M in Direct Offering - TipRanks
SEC Form 424B5 filed by Tempest Therapeutics Inc. - Quantisnow
Form 424B5 Tempest Therapeutics, - StreetInsider
Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor - Nasdaq
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreeme - GuruFocus
Tempest Therapeutics ends ATM prospectus with Jefferies By Investing.com - Investing.com Canada
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - The Manila Times
Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock - Nasdaq
Tempest Therapeutics announces $4.6 million registered direct offering - Investing.com
Tempest Therapeutics ends ATM prospectus with Jefferies - Investing.com
Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025SEC Filing - MarketScreener
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreement | TPST Stock News - GuruFocus
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Tempest Therapeutics Shifts Executives to Consulting Roles - TipRanks
Tempest Therapeutics stock rises on EMA Orphan Drug Designation By Investing.com - Investing.com South Africa
Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com
Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com
Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq
TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus
Tempest Receives Orphan Drug Designation from the European - GlobeNewswire
Breakthrough Liver Cancer Drug Shows 6-Month Survival Benefit, Secures Crucial EU and FDA Support - Stock Titan
Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks
HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World
Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Tempest Therapeutics Inc (TPST) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.34%
大文字化:
|
ボリューム (24 時間):